NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on surgical solutions for neurological disorders, announced today that it is expected to be added to the Russell Microcap Index as part of the first semi-annual 2026 Russell indexes reconstitution. The preliminary inclusion was based on index additions lists published by FTSE Russell on May 22, May 29, and June 5, 2026. The reconstituted indexes will take effect after the US market close on Friday, June 26, 2026.
Dave Rosa, Chief Executive Officer of NeuroOne, expressed optimism about the development, stating, “We are pleased that NeuroOne is expected to be added to the Russell Microcap Index. We believe our inclusion reflects the commercial momentum we have built across our portfolio of FDA-cleared electrode and ablation technologies, and the increasing recognition of NeuroOne within the investment community. We expect membership in the index to expand our visibility among institutional investors and broaden our shareholder base as we continue our mission of transforming the treatment of neurological disorders.”
The Russell Microcap Index is part of the broader Russell US Indexes, which FTSE Russell has announced will transition from an annual to a semi-annual reconstitution schedule starting in 2026. This change allows for more timely inclusion of eligible companies. For NeuroOne, being added to the index could lead to increased demand for its shares from index funds and institutional investors that track the Russell Microcap Index, potentially improving liquidity and valuation.
NeuroOne markets a minimally invasive and high-definition electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These solutions aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The announcement underscores the company's progress in commercializing its technologies and gaining traction in the medical device industry. For investors, inclusion in the Russell Microcap Index often signals a milestone in a company's growth trajectory, potentially attracting more attention from analysts and larger institutional investors. The broader impact on the industry could be increased awareness of NeuroOne's technologies, which may encourage adoption among healthcare providers and payers.
NeuroOne cautions that forward-looking statements in the press release involve risks and uncertainties, including those related to commercialization, market acceptance, regulatory decisions, and capital requirements. The company does not undertake an obligation to update these statements. More information about NeuroOne is available at nmtc1.com.
